NCT05957653 is a Phase 4 clinical trial of lidocaine and sufentanil in Prostate Cancer, sponsored by RenJi Hospital.

Who is sponsoring NCT05957653?

NCT05957653 is sponsored by RenJi Hospital.

What drugs are being tested in NCT05957653?

Interventions in NCT05957653: lidocaine and sufentanil, Saline.

What condition does NCT05957653 study?

NCT05957653 studies Prostate Cancer.

Is NCT05957653 still recruiting?

NCT05957653 is currently status unknown. Last updated 24 July 2023.

Last reviewed 2023-07-24 · How we verify

NCT05957653

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lidocaine Combined With Sufentanil for Preventing Catheter-related Bladder Discomfort

Status unknown Phase 4 Last updated 24 July 2023

What this trial tests

Phase 4 trial testing lidocaine and sufentanil in Prostate Cancer in 140 participants. Status unknown.

Timeline

7 October 2023

Primary endpoint
30 September 2025

30 October 2025

Quick facts

Lead sponsor	RenJi Hospital
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	140
Start date	7 October 2023
Primary completion	30 September 2025
Estimated completion	30 October 2025

Drugs / interventions tested

lidocaine and sufentanil — full drug profile →
Saline

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

RenJi Hospital

Who can join

Adults 18 to 79, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to evaluate the incidence and severity of postoperative catheter-related bladder discomfort after robot-assisted radical prostatectomy. The main question it aims to answer is to evaluate incidence of CRBD immediately after extubation in resuscitation. A total of 20ml of 2% lidocaine and 1μg/ml sufentanil or 20ml normal saline was injected into the bladder of the participants through the catheter. After drug injection, the catheter was clamped for 20 minutes, and then 100ml normal saline was injected into the bladder through the catheter to flush out. Then, the incidence of CRBD was compared between the two groups.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other RenJi Hospital trials

Trials by the same sponsor.

NCT07584733 — Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper · Phase 2 · not yet recruiting
NCT07537725 — EEG-TMS for Postoperative Delirium After Cardiac Surgery · NA · not yet recruiting
NCT07527936 — A Study of BEN301 Injection in theTreatment of Autoimmune Diseases · EARLY_PHASE1 · not yet recruiting
NCT07343076 — Efficacy of Immediate Versus Staged Complete Revascularization in Patients With NSTE-ACS and Multivessel Disease (FUTURE · NA · not yet recruiting
NCT07449793 — Biochemical Response and Clinical Outcomes in Patients With PBC · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05957653 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by RenJi Hospital
Last refreshed: 24 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05957653.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing